Mitia™ – Macregen’s biologically-based, targeted drug candidate for AMD
This first-in-class drug candidate works by removing and/or clearing accumulated lipids under the macula which are the main component of drusen deposits typically observed in patients with "dry" AMD.
Mitia™ is being developed as a disease-modifying drug that will remove the lipids that have accumulated under the macula, thereby treating the underlying cause of AMD.
This therapeutic approach is based on the similarities between the etiologic causes of AMD and another lipid and inflammation-based disease – atherosclerosis. This seismic scientific observation has been validated by compelling evidence obtained by the comparative examination of hundreds of donor eyes from people with AMD and from age-matched controls.
This work was led by Christine Curcio, PhD, Chief Scientific Officer for Macregen, and has resulted in a comprehensive understanding of the anatomical and biochemical changes in AMD, as well as the desired mode of action for a successful drug therapy.
It is envisioned that Mitia™ can be used in combination with anti-VEGF drugs that are designed to treat nAMD. Thus, both the removal of lipid deposits and the inhibition of neovascular complications may be accomplished concurrently or sequentially.